Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 5/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.37 |
| ▸ | RAB9A | P51151 | 4/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | APOBEC3A | P31941 | 2/20 | 0.37 |
| ▸ | APOBEC3G | Q9HC16 | 2/20 | 0.37 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 4/20 | 0.36 |
| ▸ | NR2F2 | P24468 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.36 |
| ▸ | GALR3 | O60755 | 1/20 | 0.36 |
| ▸ | MITF | O75030 | 1/20 | 0.33 |
| ▸ | NPY1R | P25929 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1160912 | 0.83 | APOBEC3A (0.41) | MAPTNPC1SMN1; SMN2RAB9ALMNA | |
| SCHEMBL13004982 | 0.78 | MAPT (0.34) | MAPTHPGDNPC1SMN1; SMN2RAB9A | |
| SCHEMBL9749472 | 0.78 | MAPT (0.35) | MAPTHPGDNPC1SMN1; SMN2RAB9A | |
| SCHEMBL11449820 | 0.74 | GRIN1 (0.37) | — | |
| SCHEMBL11823955 | 0.68 | MAPT (0.50) | MAPTHPGDNPC1SMN1; SMN2RAB9A | |
| SCHEMBL11021834 | 0.67 | PTPN11 (0.36) | MAPTHPGDALDH1A1 | |
| SCHEMBL28769174 | 0.65 | MAPT (0.36) | MAPTHPGDNPC1SMN1; SMN2RAB9A | |
| SCHEMBL497532 | 0.64 | MAPT (0.38) | MAPTHPGDLMNAALDH1A1 | |
| SCHEMBL4837023 | 0.64 | — | — | |
| SCHEMBL24581679 | 0.64 | OPRM1 (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11739066-B2 | Method for fluoroalkylation of enamines | ARXADA AG (CH) | 2023-08-29 | — | — | US | disclosed |
| US-11739066-B2 | Method for fluoroalkylation of enamines | ARXADA AG (CH) | 2023-08-29 | — | — | US | disclosed |
| US-20220204464-A1 | Method for Fluoroalkylation of Enamines | LONZA LTD (CH) | 2022-06-30 | — | — | US | disclosed |
| US-20120065195-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | ARRAY BIOPHARMA INC. | 2012-03-15 | — | — | US | disclosed |
| US-20120065195-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | ARRAY BIOPHARMA INC. | 2012-03-15 | — | — | US | disclosed |
| US-20120065195-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | ARRAY BIOPHARMA INC. | 2012-03-15 | — | — | US | disclosed |
| WO-2011123674-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | ARRAY BIOPHARMA INC. (US) | 2011-10-06 | — | — | WO | disclosed |
| WO-2011123674-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | ARRAY BIOPHARMA INC. (US) | 2011-10-06 | — | — | WO | disclosed |
| US-20060205772-A1 | Amide derivatives and their use as inhibitors of 11-beta-hydroxysteroid dehydrogenase type I | COPPOLA GARY M | 2006-09-14 | — | — | US | disclosed |
| EP-1590319-A1 | AMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | Novartis AG (CH) | 2005-11-02 | — | — | EP | disclosed |
| WO-2004065351-A1 | AMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | NOVARTIS AG (CH) | 2004-08-05 | — | — | WO | disclosed |
| US-4221800-A | ANTIALLERGENS, ANTIHISTAMINES | MILES LABORATORIES, INC. (US) | 1980-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060205772-A1 | Amide derivatives and their use as inhibitors of 11-beta-hydroxysteroid dehydrogenase type I | HSD11B1, HSD11B2, CYP11B1 | MAPT 4655/4885HPGD 239/4885NPC1 1136/4885 |
| US-20120065195-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | APP, BACE1, PSEN1 | MAPT 14/4885HPGD 303/4885NPC1 45/4885 |
| US-11739066-B2 | Method for fluoroalkylation of enamines | HNMT, PNMT, INMT | MAPT 3997/4885HPGD 2837/4885NPC1 959/4885 |
| US-20220204464-A1 | Method for Fluoroalkylation of Enamines | HNMT, PNMT, INMT | MAPT 3997/4885HPGD 2837/4885NPC1 959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.